These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6572894)

  • 21. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dichloromethane as an antisickling agent in sickle cell hemoglobin.
    Schoenborn BP
    Proc Natl Acad Sci U S A; 1976 Nov; 73(11):4195-9. PubMed ID: 1069309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical modification of human hemoglobin by antisickling concentrations of nitrogen mustard.
    Roth EF; Arnone A; Bookchin RM; Nagel RL
    Blood; 1981 Aug; 58(2):300-8. PubMed ID: 7248523
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantitative structure-activity relationship of phenoxy and benzyloxy acid derivatives as antisickling agents.
    Mahran MA
    Boll Chim Farm; 2000; 139(2):73-80. PubMed ID: 10920532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
    Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
    Manning JM; Acharya AS
    Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative diaspirins for modification of hemoglobin and sickle hemoglobin.
    Delaney EJ; Massil SE; Shi GY; Klotz IM
    Arch Biochem Biophys; 1984 Feb; 228(2):627-38. PubMed ID: 6696450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sickle hemoglobin aggregation: a new class of inhibitors.
    Votano JR; Gorecki M; Rich A
    Science; 1977 Jun; 196(4295):1216-9. PubMed ID: 870976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Location of potential binding sites on deoxy hemoglobin for the design of antigelling agents.
    Manavalan P; Prabhakaran M; Johnson ME
    J Mol Biol; 1992 Feb; 223(3):791-800. PubMed ID: 1542119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A structure-guided approach to ameliorate sickle cell disease.
    Richter-Addo GB
    Acta Crystallogr D Struct Biol; 2018 Nov; 74(Pt 11):1039-1040. PubMed ID: 30387762
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.
    Li Q; Henry ER; Hofrichter J; Smith JF; Cellmer T; Dunkelberger EB; Metaferia BB; Jones-Straehle S; Boutom S; Christoph GW; Wakefield TH; Link ME; Staton D; Vass ER; Miller JL; Hsieh MM; Tisdale JF; Eaton WA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E689-E696. PubMed ID: 28096387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5'-deoxypyridoxal as a potential anti-sickling agent.
    Benesch R; Benesch RE; Edalji R; Suzuki T
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1721-3. PubMed ID: 266212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand kinetics of hemoglobin S containing erythrocytes.
    Harrington JP; Elbaum D; Bookchin RM; Wittenberg JB; Nagel RL
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):203-6. PubMed ID: 264675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
    Sablayrolles M; Wajcman H; Castaigne JP; Labie D
    Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methyl acetyl phosphate, a new type of antisickling agent: site-specific acetylating agent toward the 2,3-DPG binding site in hemoglobin S.
    Ueno H; Manning JM
    Am J Pediatr Hematol Oncol; 1988; 10(4):348-50. PubMed ID: 3239714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of citrate agar electrophoresis in evaluation of antisickling agents.
    Wilson E; Winter WP
    J Natl Med Assoc; 1981 Feb; 73(2):111-6. PubMed ID: 7205973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
    Kennedy PE; Williams FL; Abraham DJ
    J Med Chem; 1984 Feb; 27(2):103-5. PubMed ID: 6694161
    [No Abstract]   [Full Text] [Related]  

  • 40. Thermodynamics of anti-sickling agents with hemoglobin S.
    Benedict RC; Richey B; Fall L; Gill SJ; Nagel RL; Wyman J
    J Mol Biol; 1981 Aug; 150(3):423-34. PubMed ID: 7299823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.